Deals
Sanofi to Buy Inhibrx for $2.2 Billion in Rare-Disease Push
- French company will buy biotech for rare genetic disease drug
- Inhibrx to spin off new entity with rest of research, workers
This article is for subscribers only.
Sanofi agreed to buy the US biotech Inhibrx Inc. for as much as $2.2 billion, giving the French drugmaker a potential therapy for a genetic disorder that affects the lungs and liver.
The acquisition is the latest in a string of small- and mid-sized deals as Sanofi looks to double down on innovative medicines and reduce its reliance on the blockbuster asthma medicine Dupixent.